Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

Detalles Bibliográficos
Autores principales: Adnan Awad, Shady, Brück, Oscar, Shanmuganathan, Naranie, Jarvinen, Timo, Lähteenmäki, Hanna, Klievink, Jay, Ibrahim, Hazem, Kytölä, Soili, Koskenvesa, Perttu, Hughes, Timothy P., Branford, Susan, Kankainen, Matti, Mustjoki, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021312/
https://www.ncbi.nlm.nih.gov/pubmed/35443743
http://dx.doi.org/10.1038/s41408-022-00667-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021312/
https://www.ncbi.nlm.nih.gov/pubmed/35443743
http://dx.doi.org/10.1038/s41408-022-00667-9

Ejemplares similares